Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Gross Profit (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Gross Profit for 17 consecutive years, with $146.8 million as the latest value for Q4 2025.

  • Quarterly Gross Profit fell 2.72% to $146.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $576.6 million through Dec 2025, down 1.5% year-over-year, with the annual reading at $576.6 million for FY2025, 1.5% down from the prior year.
  • Gross Profit for Q4 2025 was $146.8 million at Myriad Genetics, up from $143.8 million in the prior quarter.
  • The five-year high for Gross Profit was $183.7 million in Q2 2021, with the low at $59.1 million in Q4 2022.
  • Average Gross Profit over 5 years is $131.1 million, with a median of $134.2 million recorded in 2023.
  • The sharpest move saw Gross Profit soared 107.1% in 2021, then crashed 48.61% in 2022.
  • Over 5 years, Gross Profit stood at $115.0 million in 2021, then plummeted by 48.61% to $59.1 million in 2022, then surged by 38.75% to $82.0 million in 2023, then skyrocketed by 84.02% to $150.9 million in 2024, then dropped by 2.72% to $146.8 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $146.8 million, $143.8 million, and $151.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.